Evidence Grade E — Very limited evidence. 0 published studies. 0 registered clinical trials.
Medically reviewed by a licensed medical professional
NA-Selank (N-Acetyl Selank) is a modified version of Selank, a Russian-developed anxiety peptide. The modification is proposed to improve stability. No published clinical or preclinical studies exist specifically on NA-Selank — all claims are extrapolated from the parent compound Selank, which itself has limited Western evidence.
NA-Selank is also known by these brand and alternate names:
No published studies found on PubMed.
NA-Selank has no marketing authorisation in any jurisdiction. No published clinical or preclinical studies exist specifically on this compound. All claims about its activity are extrapolated from the parent compound Selank (#107).
The absence of any compound-specific data means that the effects of N-acetylation on pharmacology, safety, and efficacy are unknown. Products available through unregulated channels lack pharmaceutical quality assurance.
No studies specific to NA-Selank have been published. The proposed mechanism is derived entirely from research on the parent compound Selank, which suggests GABAergic modulation. Whether the N-acetyl modification alters the pharmacological profile is not established.
No studies of any kind have been published specifically on NA-Selank. All proposed properties are extrapolated from parent Selank research, which itself consists of only 3-4 published clinical studies, all from Russian institutions. Whether the N-acetyl modification alters pharmacology beyond stability is unknown. Even the parent compound lacks Western-standard randomised controlled trials. Products from unregulated channels lack pharmaceutical quality assurance.
PeptideTrace tracks 0 registered clinical trials for NA-Selank sourced from ClinicalTrials.gov.
No trials registered on ClinicalTrials.gov for this compound.
NA-Selank (N-Acetyl Selank) is the N-acetylated form of Selank, a synthetic heptapeptide analogue of the endogenous immunomodulatory peptide tuftsin. Its sequence is Ac-Thr-Lys-Pro-Arg-Pro-Gly-Pro, with molecular formula C35H59N11O10 and molecular weight 793.92 g/mol (CAS: 2212313-10-6 for the amidate form). The N-acetyl modification protects the N-terminus from aminopeptidase degradation, the primary route of Selank's rapid clearance. Parent Selank has a plasma half-life of approximately 2 minutes; research suggests NA-Selank has significantly extended stability, though no direct pharmacokinetic data have been published. Many vendors sell the doubly-modified N-Acetyl Selank Amidate (Ac-Thr-Lys-Pro-Arg-Pro-Gly-Pro-NH2), which adds C-terminal amidation for additional carboxypeptidase protection. Administration is primarily intranasal. Not approved by any regulatory agency.
Research suggests NA-Selank shares the pharmacodynamic profile of parent Selank, with the N-acetyl group primarily conferring pharmacokinetic advantages. The mechanism derives entirely from Selank research: allosteric modulation of GABA-A receptors (altering the number of GABA binding sites without affecting receptor affinity), with transcriptomic studies showing Selank changed expression of 45 out of 84 GABAergic neurotransmission genes in rat frontal cortex within 1 hour. Research suggests additional mechanisms include increased serotonin metabolism in the hippocampus and hypothalamus (300 ug/kg in BALB/c mice), modulation of dopamine metabolites in hippocampus and frontal cortex, rapid elevation of BDNF mRNA in the hippocampus, and inhibition of enkephalin-degrading enzymes (IC50 = 20 uM) increasing leu-enkephalin half-life. As a tuftsin analogue, immunomodulatory properties including modulation of IL-6 expression and Th1/Th2 cytokine balance are also suggested by parent compound research.
No published clinical or preclinical studies exist specifically on NA-Selank. All data derives from the parent compound Selank. The key GAD study (Zozulia et al., 2008; N=62) compared Selank (n=30) versus medazepam (n=32) and found comparable anxiolytic effects, with Selank additionally demonstrating antiasthenic and psychostimulant properties. A GAD dose-response study (N=20) showed Selank 2,700 ug/day intranasally reduced Hamilton Anxiety Rating Scale scores from 20.3 to 7.0 in rapid responders by Day 3 (p < 0.01) and from 16.1 to 6.2 in conventional responders by Day 14 (p < 0.01). A phobic-anxiety study (2014; N=60) showed anxiolytic effects lasting one week after final dose. Parent Selank was approved in Russia in 2009 as Selank 0.15% nasal drops for generalized anxiety disorder. NA-Selank has no brand name and is not approved in any jurisdiction.
The information on this page is provided for educational and research reference purposes only. This is not medical advice. Always consult a qualified healthcare professional before making any health-related decisions.
Compare prices from 1 vendor listing
View pricing data across vendors and countries for NA-Selank
Cerebrolysin has been studied in over 200 clinical trials involving more than 15,000 patients, primarily for stroke and Alzheimer's disease. The largest stroke trial (CASTA, 1,070 patients) showed no significant benefit on its primary endpoint. A Cochrane systematic review concluded that evidence was insufficient to support its routine use in stroke or dementia. Cerebrolysin is approved in some non-FDA/non-EMA jurisdictions for neurological conditions. Its clinical evidence base, despite being extensive in volume, has not met the standards required for FDA or EMA approval. The undefined molecular composition makes batch-to-batch consistency and quality standardisation inherently challenging compared to defined single-entity pharmaceuticals.
P21 has no marketing authorisation. No human clinical trials have been conducted. The evidence base consists entirely of studies in transgenic Alzheimer's disease mouse models, conducted primarily by a single research group. Animal studies reported behavioural and biochemical changes in AD mouse models following chronic oral administration. The translation of results from transgenic mouse models of Alzheimer's disease to human disease has historically been extremely poor — the vast majority of compounds showing efficacy in such models have failed in human trials. Products available through unregulated channels lack pharmaceutical quality assurance.
Semax is approved in Russia for stroke recovery and cognitive conditions. It has not been approved by the FDA, EMA, or other major Western regulatory agencies, and the clinical evidence base has not undergone Western regulatory review. Published clinical studies are predominantly Russian. The largest published study (110 stroke patients) reported correlations between treatment and BDNF levels. The evidence does not meet the standards typically required for FDA or EMA approval. Its regulatory status is limited to Russia and certain former Soviet states.
This content is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional before making decisions about your health.
